Short-term Effects of Supplemental Oxygen in Patients With IPF

NCT ID: NCT03050255

Last Updated: 2018-12-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2018-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Although exercise-induced desaturation is frequently observed in patients with idiopathic pulmonary fibrosis (IPF) short-term effects of supplemental oxygen during walking have not been investigated yet. Given, that walking ability is the most important activity of daily life, the aim of our study is to investigate the effects of supplemental oxygen on endurance walking capacity in hypoxemic IPF patients. In this study patients will perform 3 endurance shuttle walk tests (ESWTs) at 85% of their individual peak performance using medical air (=compressed room air, 2 liters/minute), 2 liters/minute oxygen, 4 liters/minute Oxygen in a double-blinded fashion and random order.

Since there are only limited pharmacological treatment options for IPF patients, this study may help to provide novel information about the short-term effects of supplemental oxygen. Furthermore it may help to investigate possibilities to optimize oxygen therapy in order to facilitate patients´ participation in activities of daily life and not at least to improve patients´ quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale:

Exercise-induced desaturation is frequently observed in patients with idiopathic pulmonary fibrosis and predicts poorer outcomes. However, prospective studies with larger sample sizes and those investigating the effect of oxygen on endurance time, oxygen saturation and breathing frequency during walking are lacking. Given that walking is the most important activity of daily life to preserve the maintenance and to participate in social life, we aim to investigate the effects of supplemental oxygen during walking in IPF patients.

The endurance shuttle walk test (ESWT) is a well validated test with high reliability and validity for measuring endurance walking capacity in patients with chronic obstructive pulmonary disease (COPD). The advantage of this test in contrast to the 6-minute walk test is that the ESWT is performed at 85% of the individual maximum that is close to the intensity of typical daily activities. Additionally, by using the ESWT it is possible to determine the maximum duration of exercise and to compare values at isotime (= time point when the shortest of the 3 ESWTs ends), whereas values at the end of different six-minute walk tests (6MWTs) are not comparable in case of different distances.

Aim:

To investigate the short-term effects of supplemental oxygen on endurance capacity during walking (ESWT) in patients with idiopathic pulmonary fibrosis.

Design:

This study is a randomized, controlled, double-blinded cross-over trial. Following an initial incremental shuttle walk test (ISWT) in order to determine the individual maximum walking capacity, patients will perform 3 endurance shuttle walk tests (ESWT) at 85% of the maximal pace. In randomized order, patients will complete one ESWT on 2l/min oxygen, one on 4l/min oxygen and one on medical air (=compressed room air), whereas the patients as well as the investigator will be blinded to the gas mixture provided. All 3 conditions will be provided via nasal cannula. The time between the two ESWTs will be 24 hours in order to give enough time for regeneration. Endurance Walking capacity as measured by the ESWT will be used as the primary outcome.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Idiopathic Pulmonary Fibrosis (IPF)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ESWT order 1

Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:

1. medical air (MA)
2. Oxygen (2 Liter/min)
3. Oxygen (4 Liter/min)

Group Type EXPERIMENTAL

Medical air

Intervention Type OTHER

Oxygen (2Liter/min)

Intervention Type OTHER

Oxygen (4Liter/min)

Intervention Type OTHER

ESWT order 2

Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:

1. medical air (MA)
2. Oxygen (4 Liter/min)
3. Oxygen (2 Liter/min)

Group Type EXPERIMENTAL

Medical air

Intervention Type OTHER

Oxygen (2Liter/min)

Intervention Type OTHER

Oxygen (4Liter/min)

Intervention Type OTHER

ESWT order 3

Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:

1. Oxygen (2 Liter/min)
2. Medical air (MA)
3. Oxygen (4 Liter/min)

Group Type EXPERIMENTAL

Medical air

Intervention Type OTHER

Oxygen (2Liter/min)

Intervention Type OTHER

Oxygen (4Liter/min)

Intervention Type OTHER

ESWT order 4

Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:

1. Oxygen (2 Liter/min)
2. Oxygen (4 Liter/min)
3. Medical air (MA)

Group Type EXPERIMENTAL

Medical air

Intervention Type OTHER

Oxygen (2Liter/min)

Intervention Type OTHER

Oxygen (4Liter/min)

Intervention Type OTHER

ESWT order 5

Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:

1. Oxygen (4 Liter/min)
2. Medical air (MA)
3. Oxygen (2 Liter/min)

Group Type EXPERIMENTAL

Medical air

Intervention Type OTHER

Oxygen (2Liter/min)

Intervention Type OTHER

Oxygen (4Liter/min)

Intervention Type OTHER

ESWT order 6

Subject performs endurance shuttle walk tests (ESWT) under following conditions in the following order:

1. Oxygen (4 Liter/min)
2. Oxygen (2 Liter/min)
3. Medical air (MA)

Group Type EXPERIMENTAL

Medical air

Intervention Type OTHER

Oxygen (2Liter/min)

Intervention Type OTHER

Oxygen (4Liter/min)

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medical air

Intervention Type OTHER

Oxygen (2Liter/min)

Intervention Type OTHER

Oxygen (4Liter/min)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with idiopathic pulmonary fibrosis and hypoxemia at rest or during exercise (PaO2 \<55 mmHg or SpO2 \<88%)
* Written informed consent

Exclusion Criteria

* Forced vital capacity \< 50% pred.
* Clinical signs of any cardial comorbidity
* Not able to walk
* Oxygen flow needed during exercise \> 4l/min
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Linde AG

INDUSTRY

Sponsor Role collaborator

Schön Klinik Berchtesgadener Land

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Klaus Kenn

Prof. Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Klaus Kenn, Prof.

Role: PRINCIPAL_INVESTIGATOR

Schoen Klinik Berchtesgadener Land

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Schoen Klinik Berchtesgadener Land

Schönau am Königssee, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IPF-O2-Study

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.